Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

MS trials. The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events. Eligible patients in this trial are now receiving dirucotide on an un-blinded basis to the end of their 27th month in the trial.

Licensing and Development Agreement with Lilly

On December 17, 2007, BioMS entered into a licensing and development agreement (the "Agreement") granting Lilly exclusive worldwide rights to dirucotide. The transaction closed on January 25, 2008 and BioMS received an upfront payment of US $87 million. In September 2008, BioMS received a development milestone payment of US $10 million as a result of the positive interim analysis from the DSMB for MASESTRO-01. BioMS has the potential to receive future development and sales milestones up to US $400 million and escalating royalties on sales if dirucotide is commercialized.

Not later than sixty (60) days following receipt of the final written report of the results of the MAESTRO-01 trial, Lilly shall notify BioMS in writing whether Lilly will terminate the Agreement or alternatively Lilly shall bear 100% of any and all continuing development costs incurred by Lilly or BioMS for dirucotide.

HYC750 and BioCyDex

On May 9, 2008, BioMS entered into a Royalty and Assignment Agreement with Orcrist Bio. Inc. for HYC750, a technology based on hyaluronic acid that has a number of potential therapeutic uses and is being developed as a treatment for the side effects of chemotherapy. BioMS held an exclusive worldwide license to HYC750 from the University of Alberta. As a result of the Royalty and Assignment Agreement, BioMS terminated its license with the University of Alberta and the University entered into
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 DuPont Pioneer and ... more than double the acreage contracted for Plenish® ... its soybean crush facility in Salisbury, Md. The ... will target several markets including foodservice and food ... performance. , For the 2015 growing season, Perdue ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 Today, Nerium ... announced the winners of its “Reflect Your Youth” contest, ... not only seen a difference in their skin since ... a new outlook on life as a result of ... originated as an effort by Nerium International to inspire ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... article, the City of Milwaukee has negotiated a three-year "franchise-like" ... company to start an Internet protocol video service to compete ... will be considered by the Milwaukee Common Council, AT&T would ... by the service. , , While there are ...
... big business (untold billions of dollars every year), they also ... of the fundamental ethical principle of informed consent ... is that conducting a clinical trial carries with it the ... positive or negative or even if the clinical trial is ...
... For the second time this year, a tech-based company in ... to the public. Called an initial public offering, this kind ... and investors who are directly involved, but to others who ... Madison-based biotechnology company, has filed papers with the Securities ...
Cached Biology Technology:State video franchises vs. universal service: Grasping the total picture 2State video franchises vs. universal service: Grasping the total picture 3State video franchises vs. universal service: Grasping the total picture 4What patients want: A story of choice, clinical trials & evidence-based medicine 2What patients want: A story of choice, clinical trials & evidence-based medicine 3What patients want: A story of choice, clinical trials & evidence-based medicine 4What patients want: A story of choice, clinical trials & evidence-based medicine 5Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3
(Date:10/22/2014)... The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia ... (AFRL), has chosen a project proposed by the Arizona ... Arizona College of Medicine – Tucson ... is to assess different sweat collection methods and devices ... under a variety of human-body conditions, the results of ...
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... The next time you are stung by a ... venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs ... or diagnose cancer. This research, described in the August ... ( http://www.fasebj.org ), shows how modified melittin may revolutionize ...
... by which Helicobacter pylori , the only known cancer-causing ... The new study, in the journal Oncogene , reports ... pylori infection and stomach cancer, the second leading cause ... population is infected with H. pylori, a bacterium that can ...
... genomes that potentially hide a rich array of pharmaceutical ... antibiotic. The study, reported in the August issue of ... serious diseases that are rapidly acquiring multi-drug resistance. ... successfully used a ,genome mining, approach to find and ...
Cached Biology News:Cancer-causing bacterium targets tumor-suppressor protein 2Cancer-causing bacterium targets tumor-suppressor protein 3Mining bacterial genomes reveals valuable 'hidden' drugs 2
Ets-1...
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: